(Date:8/21/2008)... New names and fresh websit... UME/GME administration software , ... one45 Software, a leading provider of healthcare ... of Cytiva Software Inc. (CRX:TSX.V), announced to...hcare education administration products., , ,Compl...
(Date:8/20/2008)... NEWTON, Mass., Aug. 20 /PRNewswire/ -- Questex M...o-business media company and owner of,American Spa... and the,International Beauty Shows, the Internati...) and the SPATEC appointment events today announce...stry portals SpaTrade (, http://www.SpaTrade.com ...
(Date:8/20/2008)... Survey Report Is Available at http://ww...Newswire/ -- A new survey released today,documents...re leveraging,health information technology (HIT) ...The survey results highlight the need for many HIT...dization and,interoperability to optimize clinical...
(Date:8/20/2008)...use postponed reproductive onset in teen, adult fe...EDNESDAY, Aug. 20 (HealthDay News) -- Alcoholism i...ccording to a study that compared women,s and men,... age when they had their first child. , The re...ian twins born between 1893-1964 (3,634 female and...
Breaking Medicine News(10 mins):Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 2Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 3Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 4Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 2Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 3Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 2Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 3Health News:Women's Alcohol Use Tied to Delayed Childbearing 2...y may reduce the risk of kidney failure in men.// ...ad moderate consumption of alcohol weekly (about a...ne levels and reduced glomerular filtration rates ... day of alcohol. The research had moderated the dr...
...been associated to cardiovascular diseases and rec...ronary artery aneurysms. Studies have always been ...se on the health of the person. The new study was ...f cocaine abuse on the health of the heart. In co...
... to cause acute deficiency of immunity in man, a d... that a part of the body’s immunity system can and..., which has come out in the journal Nature Medicin...tibodies are successful in fighting and stalling t...
...dings of a recent study researchers say cholestero...es and keep cells healthy , however researchers al...being warehoused inside the arteries, where it bui...acks and strokes. Researchers suggest an enzyme ca...
Other Medicine News:(Date:8/20/2008)...swire/ -- BioVex Inc, a biotechnology,company deve...e prevention,of infectious disease, today announce...ory Agency (MHRA) has accepted BioVex,s Clinical T...dy testing the safety and,immunogenicity of its le...,ImmunoVEX HSV2., ImmunoVEX HSV2 is a novel live...
(Date:8/19/2008)...es to be used to identify molecular,signature of m...RNewswire-USNewswire/ -- ALS Therapy,Development I...n of an ALS,biomarker effort using blood samples c...artnerships. These ongoing projects are part of th...tered expression of genes,and proteins, at the ons...
(Date:8/18/2008)...SNewswire/ -- Boston University and Aubrey,Milunsk...an Genetics, Inc.,("CHG") and Director of the Cent...ced that CHG will no longer offer testing services..., Inc., These patented tests include tests relati...Connexin 26 mutations, developmental disorders cau...
(Date:8/18/2008)...l currently in Phase I -, PRINCETON, N.J. and SAN...s Inc., a clinical stage biotechnology company com...st life-threatening and life-altering,infectious d.... 7,371,772,B2 by the U.S. Patent and Trademark Of...st currently in Phase I development for the treatm...
Breaking Medicine Technology:BioVex Announces Regulatory Clearance to Commence a Clinical Study With ImmunoVEX HSV2; A Vaccine Candidate for Genital Herpes 2ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrig's Disease 2ALS Therapy Development Institute Partners with Clinical Centers to Establish Pathological Mechanisms of Lou Gehrig's Disease 3Corneal transplant technique shows promise in children 24043 1Corneal transplant technique shows promise in children 24043 2Environmental pollutant has sex skewing effect 4049 1Environmental pollutant has sex skewing effect 4049 2Availity Awarded Full EHNAC Accreditation 24038 1Availity Awarded Full EHNAC Accreditation 24038 2Availity Awarded Full EHNAC Accreditation 24038 3BioElectronics Corporations Commercial Resumes on Bloomberg Television 24033 1BioElectronics Corporations Commercial Resumes on Bloomberg Television 24033 2BioElectronics Corporations Commercial Resumes on Bloomberg Television 24033 3...tivity and Patient Tolerance Support Development,o...NA, Spain, April 12, 2007 /PRNewswire/ -- Intarcia...tical company,today announced final results from ...t ribavirin in treatment-naive patients,with genot... that,omega interferon in combination with ribavir...
...April 12, 2007 /PRNewswire-FirstCall/ --,CuraGen C...ta on,belinostat (PXD101), a histone deacetylase (...nt of cancer, and velafermin, a protein,being inve...is,will be presented at the upcoming American Ass...eting in Los Angeles, CA, April,14-18, 2007. A tot...
Other Medicine Technology:Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1 2Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1 3Intarcia Therapeutics Announces Final Results From a Phase 2 Study,of Injectable Omega Interferon plus Ribavirin for the Treatment of,Hepatitis C Genotype-1 4CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 2CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 3CuraGen Announces New Preclinical Results with Belinostat and,Velafermin to be Presented at AACR Annual Meeting 4...s a portable visual stimulation device, which can ... test system. Using LKCs exclusive Kurbisfeld tech...eld to meet the standards of the International Soc...(ISCEV). The stimulator provides for dim (-25 dB) ...
The SG-2002 Stand-Alone Ganzfeld produces a variety of visual stimuli, which will elicit electrical responses that can be amplified and recorded. The fourteen inch globe is painted with a highly refl
...lator is an advanced, hand-held visual stimulation...LKC system or used as a stand-alone component with...ng LKCs exclusive Kurbisfeld technology, the CMGS-...V (International Society for the Clinical Electrop...
...al color vision tests. It is specifically designed...or vision losses that accompany such disorders as ...), early optic neuritis, glaucoma, diabetic retino...s fast and accurate in quantifying congenital colo...
Medicine Products: